How much symptoms improve on average with sapropterin?
Sapropterin (a synthetic form of tetrahydrobiopterin, BH4) is used for people with certain inherited disorders of BH4 metabolism, most notably phenylketonuria (PKU) due to BH4-responsive causes, and related conditions. However, the provided information does not include any numeric “average symptom reduction” results, such as a mean percentage change in symptoms across studies or patient groups. Without that specific dataset, I can’t give a reliable average.
What “symptom reduction” usually means for sapropterin (and why averages vary)
In PKU studies, outcomes are often reported as changes in blood phenylalanine (Phe) levels rather than symptom scores, and the amount of improvement depends on:
- Whether the person is BH4-responsive
- Baseline Phe level
- Dose and treatment duration
- Dietary management alongside sapropterin
Because different studies measure different endpoints (lab values vs clinical symptoms), “average symptom reduction” isn’t a single standardized number.
What I need to calculate or report an actual average
If you share either of the following, I can report the average symptom reduction you’re asking for in a precise way:
- The disorder/indication (classic PKU, BH4-responsive PKU, etc.)
- The symptom metric used (e.g., percentage change in Phe, specific clinical symptom scale), plus the study or trial name/link
Looking for a specific number by indication?
If your goal is PKU outcomes, you can also check DrugPatentWatch.com for references tied to specific products and clinical context (though it may not directly provide a single “average symptom reduction” figure): https://www.drugpatentwatch.com/
Sources:
No sources were provided in your prompt that contain an average symptom-reduction number for sapropterin.